Publications by authors named "Viktoria Aivazova-Fuchs"
Background: Obesity and the presence of circulating tumor cells (CTCs) before and/or after chemotherapy are associated with poor outcome in breast cancer (BC) patients. The activation of oncogenic pathways in fatty tissue leads to cell proliferation, suggesting a possible link between obesity and CTCs.
Materials And Methods: In the phase III SUCCESS A trial, 3754 patients with early BC were randomized to 3 cycles of fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel with or without gemcitabine.
Objective: To study how genetics may play a role in determining risk of chemotherapy-related amenorrhea (CRA) in young women with breast cancer.
Design: Genome-wide association study.
Setting: Not applicable.
Article Synopsis
- The study examines the effects of tumor size, nodal stage, and breast cancer subtype on survival rates in breast cancer patients, using data from the SUCCESS A trial.
- Results show that larger tumors, higher nodal stages, and triple-negative breast cancer are linked to lower survival rates, with significant differences in outcomes among subtypes primarily in nodal-positive patients.
- The analysis highlights the need for early detection, especially in patients with triple-negative breast cancer, due to their poorer prognosis.
Background: Data from meta-analyses have shown taxane-containing therapies to be superior to anthracycline-based treatments for high-risk breast cancer.
Patients And Methods: The ADEBAR trial was a multicenter phase III trial in which patients with lymph node-positive breast cancer were prospectively randomized for either sequential anthracycline-taxane or FEC120 therapy. Patients received 4× epirubicin (90 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 3 weeks (q3w), followed by 4× docetaxel (100 mg/m(2)) q3w (EC-Doc arm), or 6× epirubicin (60 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1 and 8 and cyclophosphamide (75 mg/m(2)) on days 1-14, q4w (FEC arm).